Exelixis

Exelixis Liabilities

The The Liabilities of Exelixis (EXEL) as of Nov 1, 2026 is 683.10 M USD. In the previous year, The Liabilities was 703.49 M USD — a change of -2.90% (lower).

Liabilities

683.10 MUSD

YoY

-2.90%

Last updated:

In 2025, Exelixis's total liabilities amounted to 683.10 M USD, a -2.90% difference from the 703.49 M USD total liabilities in the previous year.

The Exelixis Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
134.83 M USD
Jan 1, 2019
199.70 M USD
Jan 1, 2020
258.22 M USD
Jan 1, 2021
405.62 M USD
Jan 1, 2022
583.06 M USD
Jan 1, 2023
678.45 M USD
Jan 1, 2024
703.49 M USD
Jan 1, 2025
683.10 M USD
The Exelixis Liabilities history
YEARLiabilitiesYoY
683.10 MUSD-2.90%
703.49 MUSD+3.69%
678.45 MUSD+16.36%
583.06 MUSD+43.74%
405.62 MUSD+57.08%
258.22 MUSD+29.30%
199.70 MUSD+48.11%
134.83 MUSD-63.59%
370.33 MUSD-27.13%
508.22 MUSD+16.39%
436.65 MUSD-1.39%
442.79 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Exelixis's Liabilities

Exelixis's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Exelixis's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Exelixis's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Exelixis's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Exelixis’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Exelixis stock

The Liabilities of Exelixis is 683.10 M USD in 2025.

The Liabilities of Exelixis changed from 703.49 M USD to 683.10 M USD, representing a -2.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Exelixis since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Exelixis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Exelixis

All Key Metrics — Exelixis